QuidelOrtho Corp (QDEL) Stock Down 4.2% -- Now Undervalued? GF S
QuidelOrtho Corp (QDEL) shares dropped 4.2% to $11.85, significantly below its GF Value™ of $37.20, suggesting it is undervalued by 68.1%. Despite this, a GF Score™ of 48/100 indicates mixed performance, with strong profitability but weak financial strength and growth, leading to a "Possible Value Trap" warning. The lack of insider transactions in the last three months also leaves investors to consider the underlying business fundamentals cautiously.
When Blood Compatibility Becomes a Pregnancy Risk
This article from Quantisnow discusses the critical topic of blood compatibility during pregnancy, highlighting it as a potential risk factor. It was published as a press release, with Quantisnow Plus members being alerted shortly after its dissemination. The piece is part of Quantisnow's real-time market intelligence, focusing on QuidelOrtho Corporation (QDEL) which operates in the health care sector.
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
QuidelOrtho Corporation announced that its management team will participate in two investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference. Interested parties can access live webcasts and replays on the company's investor relations website. The company is a global leader in in vitro diagnostics, committed to advancing diagnostics for a healthier future.
QuidelOrtho (QDEL) price target decreased by 34.46% to 19.25
This article reports a significant price target decrease for QuidelOrtho (QDEL) by 34.46%, setting the new target at $19.25. The content provided is minimal, only stating this change.
QuidelOrtho (QDEL) price target decreased by 34.46% to 19.25
This article reports that the price target for QuidelOrtho (QDEL) has been decreased by 34.46%, setting the new target at $19.25. The specific reasons or analysis behind this target reduction are not provided in the given content.
QuidelOrtho Corp stock (US7476011036): analysts divided as short interest climbs and sentiment weakens
QuidelOrtho Corp (QDEL) is experiencing pressure due to a significant increase in short interest and a cautious stance from analysts, with multiple "sell" and "hold" ratings. The stock is trading near multi-year lows, and the elevated short interest suggests bearish market sentiment. Despite this, the average 12-month price target indicates potential upside from current levels, though there is considerable dispersion in analyst projections.
QuidelOrtho (QDEL) price target decreased by 34.46% to 19.25
This article reports a significant 34.46% decrease in QuidelOrtho's (QDEL) price target, bringing it down to $19.25. The content indicates a potential negative outlook or re-evaluation of the company's valuation by analysts.
QDEL stock down as Q1 earnings miss estimates, revenues down Y/Y
The article states that QDEL stock is down following a miss on Q1 earnings estimates. Additionally, the company's revenues have decreased year-over-year.
QuidelOrtho (QDEL) price target decreased by 34.46% to 19.25
This article reports that the price target for QuidelOrtho (QDEL) has been significantly decreased by 34.46%, bringing it down to $19.25. The content provided is minimal, indicating this is likely a brief financial news alert.
QuidelOrtho Corp (QDEL) Shares Surge 3.0% -- What GF Score of 48 Tells Investors
QuidelOrtho Corp (QDEL) shares surged 3.0% to $11.39, trading significantly below its GF Value™ of $37.22, suggesting it might be undervalued. However, its GF Score™ of 48, especially a low Financial Strength score of 3/10, indicates potential risks and a possible value trap. While the stock's current P/E is below its historical median, the absence of insider transactions adds to the uncertainty, advising caution for investors.
QuidelOrtho: A Growing, Stable Business With A Significant Mispricing (NASDAQ:QDEL)
QuidelOrtho (NASDAQ:QDEL) is presented as a stable and growing business with significant mispricing, characterized by long-term customer contracts and a high renewal rate in its core lab testing and immunohematology divisions. Despite past free cash flow guidance misses due to accounts receivable and a projected EBITDA hit from Chinese reimbursement policy changes, the company is poised for growth with its new LEX product and has multiple levers to manage its debt, including potential asset sales. The article suggests that current headwinds are largely temporary and that significant upside exists from present valuation levels.
Jefferies downgrades QuidelOrtho (QDEL)
Jefferies has downgraded QuidelOrtho (QDEL). This action indicates a revised, less optimistic outlook on the company's financial prospects and stock performance from the investment bank. Further details regarding the specific reasons for the downgrade were not provided in the snippet.
QuidelOrtho Is Maintained at Neutral by Citigroup
Citigroup has maintained its Neutral rating on QuidelOrtho (NASDAQ: QDEL) stock. The article implies this is an update to previous coverage, although details of the rating's implications or reasons are not provided.
UBS Adjusts Price Target on QuidelOrtho to $12 From $17, Maintains Neutral Rating
UBS has lowered its price target for QuidelOrtho (QDEL) to $12 from $17, while keeping a Neutral rating on the stock. This adjustment reflects a modified outlook for the company by the analyst. Concurrently, Jefferies also downgraded QuidelOrtho to Hold from Buy and significantly reduced its price target to $12.50 from $35, indicating a broader cautious sentiment from analysts.
Jefferies downgrades QuidelOrtho (QDEL)
Jefferies has downgraded QuidelOrtho (QDEL). The article does not provide specifics on the reasons for the downgrade or the new rating.
Newtyn Management (NASDAQ: QDEL) reports 4.56M shares, 6.7% holding
Newtyn Management has reported a 6.7% beneficial ownership stake in QuidelOrtho Corporation (NASDAQ: QDEL), totaling 4,558,472 shares. This aggregate holding combines shares from Newtyn TE Partners, LP and Newtyn Partners, LP as of March 31, 2026. The ownership percentage is calculated based on 68,081,767 shares outstanding as of February 11, 2026, and Newtyn Management holds sole voting and dispositive power over these shared.
QuidelOrtho (QDEL) Loss Deepens In Q1 As Long Trailing Losses Challenge Bullish Narratives
QuidelOrtho (QDEL) reported a deeper loss in Q1 2026 with a basic EPS loss of US$1.35 and trailing 12-month net losses of US$1.21 billion. Despite a low P/S ratio and a theoretical DCF fair value significantly higher than its current share price, the company faces skepticism due to modest 3.1% revenue growth, a shrinking high-margin COVID testing segment, and no projected profitability within the next three years. This leaves investors weighing potential upside against ongoing operational risks and balance sheet strain.
QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y
QuidelOrtho Corporation (QDEL) reported first-quarter 2026 adjusted loss per share of 4 cents, missing the Zacks Consensus Estimate, despite revenues of $619.8 million surpassing expectations. The company experienced a year-over-year decline in revenues and significant contractions in gross and operating margins, primarily due to weak respiratory testing, Point of Care, and Donor Screening businesses. QDEL maintains its 2026 revenue outlook but lowered its adjusted EPS guidance, with financial concerns including operating cash outflow and elevated debt levels.
QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2026 Earnings Call Transcript
QuidelOrtho Corporation reported Q1 2026 earnings, missing expectations with an EPS of $-0.04. The company's results were impacted by a significantly milder respiratory season and macroeconomic headwinds, particularly in China due to anticipated IVD pricing guidelines. Despite these challenges, QuidelOrtho is progressing with strategic initiatives, including the acquisition of Lex Diagnostics and new product launches, anticipating stronger performance and positive cash flow in the second half of the year.
QuidelOrtho forecasts $2.7B-$2.75B 2026 revenue while targeting $100M-$120M free cash flow amid China pricing uncertainty
QuidelOrtho is projecting revenues between $2.7 billion and $2.75 billion for 2026, alongside a target of $100 million to $120 million in free cash flow. This forecast comes as the company navigates uncertainties related to pricing in the Chinese market. The financial outlook suggests the company's strategic goals despite potential challenges.
QuidelOrtho Reports First Quarter 2026 Financial Results
QuidelOrtho Corporation announced its financial results for the first quarter ended March 29, 2026, reporting total revenue of $620 million. The company experienced a weaker respiratory season and business disruptions in China and the Middle East, leading to a GAAP net loss of $92 million. Despite this, QuidelOrtho updated its full-year 2026 financial guidance, reflecting these market dynamics, while emphasizing strategic acquisitions like LEX Diagnostics and key product launches for future growth.
QuidelOrtho Q1 2026 slides: revenue falls 13%, respiratory weakness pressures margins
QuidelOrtho reported a challenging Q1 2026 with revenue falling 13% to $620 million and an adjusted diluted loss per share of $0.04, significantly missing analyst expectations. The decline was largely driven by a 43.6% drop in respiratory revenue and weakness in North America and China, leading to a nearly 6% share price decrease and a downward revision of full-year 2026 guidance. Despite the setbacks, the company is pursuing strategic initiatives like the acquisition of LEX Diagnostics and new product launches to strengthen its market position.
QuidelOrtho (NASDAQ: QDEL) posts Q1 2026 loss as revenue declines 11%
QuidelOrtho (NASDAQ: QDEL) reported a significant decline in its Q1 2026 financial results, with revenue falling 11% year-over-year to $619.8 million and a net loss of $91.8 million, or $1.35 per share. This downturn was primarily driven by reduced demand for U.S. respiratory products, the termination of a joint business with Grifols, and the wind-down of its U.S. donor screening portfolio, despite growth in international markets and molecular diagnostics. The company is implementing an Optimization Plan to achieve $50 million in net cost savings by 2027 and recently acquired LEX Diagnostics to bolster its molecular diagnostics offerings.
Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q1 Revenue $619.8M, vs. FactSet Est of $665.2M
QuidelOrtho Corporation (QDEL) reported its Q1 revenue at $619.8 million, falling short of the FactSet estimate of $665.2 million. The company also posted a Q1 adjusted loss of $0.04 per share. This financial update indicates that the company's first-quarter performance did not meet analyst expectations.
QuidelOrtho (NASDAQ: QDEL) trims 2026 outlook after Q1 revenue and margin decline
QuidelOrtho reported a weaker first quarter 2026 with revenue down 10.5% and a widened GAAP net loss, leading the company to reduce its full-year 2026 financial guidance. This decline was attributed to a weaker respiratory season, slower China distributor sales, and Middle East disruptions. Despite the setbacks, QuidelOrtho highlighted strategic acquisitions and new product launches as key components for long-term growth.
Quidel Q1 2026 earnings preview
This article provides an earnings preview for Quidel's Q1 2026 financial results. It indicates that the content is a preview for an upcoming earnings report.
QuidelOrtho Corp. Hits New 52-Week Low at $10.86 Amid Ongoing Struggles
QuidelOrtho Corp. has recorded a new 52-week low of $10.86, marking a significant 72.67% decline in its stock price over the past year. The company, a small-cap player in the Pharmaceuticals & Biotechnology sector, has consistently underperformed, reporting negative results for 12 consecutive quarters and exhibiting financial struggles such as a high debt-equity ratio and negative return on equity. This performance is notably below the S&P 500's positive return, highlighting the challenges QuidelOrtho faces in a competitive market.
LEX Diagnostics acquired by QuidelOrtho Corporation for $100m six years after launch
LEX Diagnostics, a company spun out of TTP Group, has been acquired by QuidelOrtho Corporation for $100 million. This acquisition follows the FDA 510(k) clearance and CLIA waived status for LEX VELO System, a breakthrough molecular diagnostics platform designed for ultra-fast point-of-care PCR testing for respiratory pathogens. QuidelOrtho plans a US commercial launch later this year, aiming to expand its presence in point-of-care molecular diagnostics.
QuidelOrtho (QDEL) price target decreased by 18.10% to 29.38
This article reports a significant decrease in QuidelOrtho's (QDEL) price target, which has been reduced by 18.10% to $29.38. This specific financial adjustment indicates a revised outlook on the company's valuation.
Vanguard holds 4,088,168 shares of QuidelOrtho (NASDAQ: QDEL)
Vanguard Portfolio Management reported beneficial ownership of 4,088,168 shares, or 6%, of QuidelOrtho (NASDAQ: QDEL) common stock as of March 31, 2026. The filing, a Schedule 13G, indicates that Vanguard holds sole dispositive power over all these shares and sole voting power over 56,400 shares. This disclosure highlights Vanguard's significant but passive investment in the diagnostic company.
QuidelOrtho (QDEL) Expected to Announce Quarterly Earnings on Tuesday
QuidelOrtho (QDEL) is expected to release its Q1 2026 earnings on Tuesday, May 5th, with analysts anticipating $0.43 EPS and $680.583 million in revenue. The company recently reported Q4 2025 earnings of $0.46 EPS on $723.6 million in revenue, surpassing estimates, but it still maintains a negative net margin of 41.46%. Despite a "Reduce" consensus rating from analysts and recent price target decreases, insider buying has been noted.
QuidelOrtho Corp (QDEL) Shares Surge 6.1% -- What GF Score of 60 Tells Investors
QuidelOrtho Corp (QDEL) shares surged 6.1% to $12.29. The stock is considered 69.0% undervalued based on its GF Value™ of $39.69, despite a GF Score™ of 60/100, which suggests above-average potential with concerns in financial strength and valuation. Insider buying activities further indicate a positive sentiment from executives.
QuidelOrtho completes $100m acquisition of LEX Diagnostics from TTP
QuidelOrtho Corporation has completed its $100 million acquisition of LEX Diagnostics from Cambridge-based TTP Group, following FDA clearance and CLIA waiver for LEX’s VELO molecular diagnostics platform in February 2026. The LEX VELO System provides rapid, highly sensitive RT-PCR testing for Influenza A, Influenza B, and COVID-19, supporting quick clinical decision-making at the point of care. This acquisition is a key step in QuidelOrtho's strategy to accelerate its growth in the molecular diagnostics market.
TTP Group sells LEX Diagnostics to QuidelOrtho to scale PCR tech
TTP Group has sold LEX Diagnostics, a company specializing in rapid PCR technology, to QuidelOrtho. This acquisition is expected to enable LEX Diagnostics to scale its innovative rapid PCR test for respiratory infections, benefiting from QuidelOrtho's established market presence in diagnostic solutions. The sale underscores the successful incubation and development of breakthrough health technologies by TTP Group.
QuidelOrtho (QDEL) COO reports RSU vesting and tax share withholding
QuidelOrtho Corp's Chief Operations Officer, Philip D. McLellan, reported routine equity compensation activity. On April 22, 2026, 3,238 restricted stock units (RSUs) vested, and 1,162 shares were withheld by the company at $11.90 each to cover tax obligations. After these transactions, McLellan directly holds 22,412 common shares, with an additional 3,238 RSUs scheduled to vest on April 22, 2027.
Understanding and Addressing Syphilis Trends - and What's Being Missed
QuidelOrtho Corporation has released a podcast episode discussing evolving syphilis trends in the U.S., highlighting a troubling rise in congenital syphilis cases despite a decline in early-stage infections. The episode emphasizes missed screening opportunities during pregnancy and suggests actionable steps such as repeat testing and utilizing all pregnancy-related encounters for screening, to combat this preventable condition.
TTP Group sells LEX Diagnostics to QuidelOrtho to scale PCR tech
The article states that MSN is the content. Without further details, it's impossible to summarize the sale of LEX Diagnostics by TTP Group to QuidelOrtho beyond the headline. The transaction likely involves scaling PCR technology, but no further information is available.
QuidelOrtho: $100 Million Acquisition Of LEX Diagnostics Completed To Expand Ultra-Fast PCR Testing
QuidelOrtho has completed the acquisition of LEX Diagnostics for approximately $100 million, enhancing its point-of-care molecular diagnostics portfolio. This acquisition includes the LEX VELO System, an ultra-fast RT-PCR platform for Influenza A, B, and COVID-19, which received FDA 510(k) clearance and CLIA waiver in February 2026. The move aims to accelerate growth in diagnostics by providing rapid, lab-quality results in decentralized care environments, with a U.S. commercial launch expected later in 2026.
QuidelOrtho completes LEX Diagnostics buy for $100 million By Investing.com
QuidelOrtho Corporation has announced the completion of its acquisition of LEX Diagnostics for approximately $100 million in cash. This acquisition adds the LEX VELO System, a molecular diagnostics platform providing rapid testing for Influenza A, B, and COVID-19, enhancing QuidelOrtho's molecular diagnostics portfolio. Despite the strategic acquisition, QuidelOrtho's stock has declined, and the company recently preannounced weaker-than-expected first-quarter results due to a soft respiratory season and other market challenges.
QuidelOrtho acquires molecular diagnostics firm LEX Diagnostics By Investing.com
QuidelOrtho has acquired LEX Diagnostics Limited, a UK-based molecular diagnostics company known for its rapid point-of-care PCR testing platform, VELO system. The acquisition occurs while QuidelOrtho's stock is near its 52-week low, but analysts anticipate a return to profitability this year. The VELO system, cleared by the FDA, offers quick PCR results for common respiratory infections, expanding QuidelOrtho's diagnostics portfolio.
TTP Group announces sale of LEX Diagnostics to QuidelOrtho
TTP Group has announced the sale of LEX Diagnostics, a UK-based molecular diagnostics company, to QuidelOrtho (QDEL). LEX Diagnostics, a spin-out of TTP, developed a point-of-care molecular testing platform, the VELO system, which delivers PCR results for Flu A, Flu B, and COVID-19 in minutes. The VELO system received U.S. Food and Drug Administration 510(k) clearance and CLIA waived status in February 2026, enabling rapid diagnosis and quicker clinical decisions.
QuidelOrtho Completes $100 Million Acquisition of LEX Diagnostics to Expand Rapid Molecular Testing
QuidelOrtho has acquired LEX Diagnostics for approximately $100 million, enhancing its rapid molecular testing capabilities. This acquisition includes the FDA-cleared LEX VELO System, a platform that provides multiplex RT-PCR results for Influenza A, B, and COVID-19 in minutes, suitable for point-of-care settings. The move aims to diversify QuidelOrtho's diagnostics portfolio and strengthen its position in the growing market for near-patient testing.
QuidelOrtho Completes Acquisition of LEX Diagnostics and Molecular Testing Platform
QuidelOrtho Corp has finalized its acquisition of LEX Diagnostics for approximately $100 million in cash. This deal brings the LEX VELO System, an ultra-fast molecular diagnostics platform cleared by the FDA for Influenza A, Influenza B, and COVID-19 testing, into QuidelOrtho's point-of-care portfolio. The acquisition aims to accelerate QuidelOrtho’s growth in the point-of-care molecular diagnostics market and support rapid clinical decision-making.
QuidelOrtho: $100 Million Acquisition Of LEX Diagnostics Completed To Expand Ultra-Fast PCR Testing
QuidelOrtho Corporation has acquired LEX Diagnostics for approximately $100 million, enhancing its point-of-care molecular diagnostics portfolio with the LEX VELO System. This ultra-fast RT-PCR platform provides rapid results for Influenza A, B, and COVID-19, having recently received FDA 510(k) clearance and CLIA waiver. The acquisition aims to expand QuidelOrtho's molecular diagnostics capabilities and improve patient outcomes through faster clinical decision-making.
QuidelOrtho Corporation (NASDAQ:QDEL) Given Consensus Rating of "Reduce" by Brokerages
Brokerages have assigned QuidelOrtho Corporation (NASDAQ:QDEL) a consensus "Reduce" rating, with an average 12-month price target of $28.25. The company's shares opened at $12.71, well below its 50-day and 200-day moving averages. Despite recent insider buying by a director and the CFO in February, and approximately 99% institutional ownership, analysts have lowered price targets for the diagnostics company.
10-minute flu and COVID PCR test joins QuidelOrtho in $100M deal
QuidelOrtho has successfully acquired LEX Diagnostics for approximately $100 million, integrating the FDA-cleared and CLIA-waived LEX VELO System into its molecular diagnostics portfolio. This rapid PCR platform delivers multiplex Influenza A/B and COVID-19 results within 6-10 minutes. The acquisition aims to expand QuidelOrtho's point-of-care offerings, with a U.S. commercial launch anticipated later in 2026.
PCR results in 6 minutes: QuidelOrtho buys LEX Diagnostics
QuidelOrtho Corporation has acquired LEX Diagnostics Limited, a UK-based molecular diagnostics company spun out of TTP Group. LEX Diagnostics is known for its VELO system, which provides ultra-fast, lab-quality PCR results for Flu A, Flu B, and COVID-19 in minutes, and recently received FDA 510(k) clearance and CLIA waived status. This acquisition enhances QuidelOrtho's point-of-care diagnostics capabilities, allowing for faster diagnoses and clinical decisions.
QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
QuidelOrtho Corporation announced the completion of its acquisition of LEX Diagnostics for approximately $100 million, marking a significant step in accelerating its growth in point-of-care molecular diagnostics. This acquisition integrates LEX's VELO System, an ultra-fast PCR platform that provides rapid diagnostic results, into QuidelOrtho's portfolio. The LEX VELO System received FDA 510(k) clearance and CLIA waiver in February 2026, with a U.S. commercial launch anticipated later this year.
QuidelOrtho Completes Acquisition of LEX Diagnostics for $100 Million
QuidelOrtho (QDEL) has finalized its acquisition of LEX Diagnostics for $100 million. The healthcare diagnostics company announced the completion on Monday, April 20, 2026. This acquisition is expected to bolster QuidelOrtho's portfolio in in vitro diagnostics.
QuidelOrtho acquires molecular diagnostics firm LEX Diagnostics
QuidelOrtho Corporation has acquired LEX Diagnostics Limited, a UK-based molecular diagnostics company known for its rapid point-of-care PCR testing platform. The acquisition brings the FDA-cleared VELO system, which quickly tests for Flu A, Flu B, and COVID-19, into QuidelOrtho's portfolio. This move comes as QuidelOrtho's stock trades near its 52-week low, although analysts anticipate profitability this year.
